Outset Medical, Inc. (NASDAQ:OM) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Moderate Buy consensus from five analysts (1 sell, 1 hold, 2 buy, 1 strong buy) with an average 12‑month price target of $10.00.
• Shares are trading well below last year's peak — opened at $4.33 with a 1‑year low/high of $3.00/$21.98, a market cap of $80.23 million, a negative P/E (-0.64), and 50/200‑day moving averages of $3.82/$5.44.
• Outset's flagship Tablo Hemodialysis System aims to simplify dialysis delivery, and recent institutional activity includes XTX Topco raising its stake to 100,612 shares (up 876.9%, ~ $373k), indicating modest investor interest.

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $10.00.

A number of equities analysts recently issued reports on OM shares. Stifel Nicolaus decreased their target price on Outset Medical from $14.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Outset Medical in a report on Friday, March 27th. BTIG Research dropped their price target on Outset Medical from $17.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, February 12th. Finally, Wall Street Zen downgraded Outset Medical from a "hold" rating to a "sell" rating in a report on Saturday, April 11th.

Outset Medical Price Performance

NASDAQ OM opened at $4.33 on Tuesday. Outset Medical has a 1 year low of $3.00 and a 1 year high of $21.98. The business's fifty day moving average is $3.82 and its two-hundred day moving average is $5.44. The stock has a market capitalization of $80.23 million, a P/E ratio of -0.64 and a beta of 1.92. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.40 and a current ratio of 6.67.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in OM. R Squared Ltd purchased a new stake in shares of Outset Medical in the 1st quarter valued at approximately $65,000. Hsbc Holdings PLC purchased a new position in Outset Medical during the 4th quarter worth approximately $46,000. Aristides Capital LLC purchased a new position in Outset Medical during the 4th quarter worth approximately $177,000. XTX Topco Ltd raised its stake in Outset Medical by 876.9% during the 4th quarter. XTX Topco Ltd now owns 100,612 shares of the company's stock valued at $373,000 after purchasing an additional 90,313 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in shares of Outset Medical in the fourth quarter valued at $186,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.